+

WO2007014167A3 - Compositions et procedes pour le traitement de maladies epitheliales avec des facteurs de croissance - Google Patents

Compositions et procedes pour le traitement de maladies epitheliales avec des facteurs de croissance Download PDF

Info

Publication number
WO2007014167A3
WO2007014167A3 PCT/US2006/028699 US2006028699W WO2007014167A3 WO 2007014167 A3 WO2007014167 A3 WO 2007014167A3 US 2006028699 W US2006028699 W US 2006028699W WO 2007014167 A3 WO2007014167 A3 WO 2007014167A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
growth factors
treating epithelial
epithelial diseases
Prior art date
Application number
PCT/US2006/028699
Other languages
English (en)
Other versions
WO2007014167A2 (fr
Inventor
Kristen Pierce
Ge Wu
Aileen Zhou
William Roscoe
Stephen Doberstein
Original Assignee
Five Prime Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Five Prime Therapeutics, Inc. filed Critical Five Prime Therapeutics, Inc.
Publication of WO2007014167A2 publication Critical patent/WO2007014167A2/fr
Publication of WO2007014167A3 publication Critical patent/WO2007014167A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention a trait à des compositions et procédés pour le traitement de maladies épithéliales telles que la mucosite et la maladie intestinale inflammatoire chez un sujet. L'invention a également trait à des agents thérapeutiques à action prolongée capables de favoriser la survie d'un kératinocyte oral ou d'une cellule épithéliale intestinale.
PCT/US2006/028699 2005-07-22 2006-07-24 Compositions et procedes pour le traitement de maladies epitheliales avec des facteurs de croissance WO2007014167A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70206505P 2005-07-22 2005-07-22
US60/702,065 2005-07-22

Publications (2)

Publication Number Publication Date
WO2007014167A2 WO2007014167A2 (fr) 2007-02-01
WO2007014167A3 true WO2007014167A3 (fr) 2009-09-17

Family

ID=37683889

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/028699 WO2007014167A2 (fr) 2005-07-22 2006-07-24 Compositions et procedes pour le traitement de maladies epitheliales avec des facteurs de croissance

Country Status (1)

Country Link
WO (1) WO2007014167A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3591398A1 (fr) * 2011-08-15 2020-01-08 Children's Hospital Los Angeles Méthodes de criblage d'activateurs de erbb4 qui inhibent l'apoptose de cellules cibles
WO2019231860A1 (fr) * 2018-05-27 2019-12-05 The Board Of Trustees Of The Leland Stanford Junior University Procédé de traitement ou de prévention de la mucosite orale associée à une radiothérapie et à une chimiothérapie utilisant un facteur de croissance de type facteur de croissance épidermique se liant à l'héparine (hb-egf) administré par voie locale
JP2017537067A (ja) * 2014-10-21 2017-12-14 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー ヘパリン結合性上皮成長因子様成長因子を用いた、扁桃摘出後の上皮再生促進の方法
EP3355909B1 (fr) 2015-09-28 2023-06-07 Children's Hospital Los Angeles Méthodes de traitement de maladies à médiation par les macrophages pro-inflammatoires positifs à l'erbb4
WO2020031204A1 (fr) * 2018-08-08 2020-02-13 Sree Chitra Tirunal Institute For Medical Science And Technology Facteur de croissance transformant (tgf) recombinant à des fins de cicatrisation de plaies et son procédé
EP4126000A1 (fr) * 2020-03-31 2023-02-08 Universität Heidelberg Agents destinés à être utilisés dans le traitement thérapeutique ou prophylactique de maladies associées à l'épithélium pigmentaire de la rétine

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991012018A1 (fr) * 1990-02-13 1991-08-22 Gropep Pty. Ltd. Procede de traitement de troubles intestinaux
WO1992003155A1 (fr) * 1990-08-24 1992-03-05 Kabi Pharmacia Ab Produit contenant un facteur de croissance et de la glutamine et utilisation d'un facteur de croissance dans le traitement des muqueuses intestinales
WO1996037216A1 (fr) * 1995-05-22 1996-11-28 Genentech, Inc. Procede d'administration de l'igf-i
WO1998011904A1 (fr) * 1996-09-20 1998-03-26 Scientific Hospital Supplies International Limited Prevention du delabrement gastro-intestinal
US6319899B1 (en) * 1997-09-17 2001-11-20 The Nemours Foundation Method and composition for the treatment of inflammatory bowel disease
US20030144202A1 (en) * 1996-10-15 2003-07-31 Amgen Inc. Uses of keratinocyte growth factor-2
US20030171267A1 (en) * 2000-04-12 2003-09-11 Rosen Craig A. Albumin fusion proteins
US20040136952A1 (en) * 2002-12-26 2004-07-15 Mountain View Pharmaceuticals, Inc. Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991012018A1 (fr) * 1990-02-13 1991-08-22 Gropep Pty. Ltd. Procede de traitement de troubles intestinaux
WO1992003155A1 (fr) * 1990-08-24 1992-03-05 Kabi Pharmacia Ab Produit contenant un facteur de croissance et de la glutamine et utilisation d'un facteur de croissance dans le traitement des muqueuses intestinales
WO1996037216A1 (fr) * 1995-05-22 1996-11-28 Genentech, Inc. Procede d'administration de l'igf-i
WO1998011904A1 (fr) * 1996-09-20 1998-03-26 Scientific Hospital Supplies International Limited Prevention du delabrement gastro-intestinal
US20030144202A1 (en) * 1996-10-15 2003-07-31 Amgen Inc. Uses of keratinocyte growth factor-2
US6319899B1 (en) * 1997-09-17 2001-11-20 The Nemours Foundation Method and composition for the treatment of inflammatory bowel disease
US20030171267A1 (en) * 2000-04-12 2003-09-11 Rosen Craig A. Albumin fusion proteins
US20040136952A1 (en) * 2002-12-26 2004-07-15 Mountain View Pharmaceuticals, Inc. Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity

Also Published As

Publication number Publication date
WO2007014167A2 (fr) 2007-02-01

Similar Documents

Publication Publication Date Title
IL186814A0 (en) Methods, compositions and articles of manufacture for enhancing survivability of cells, tissues, organs and organisms
HUS1800021I1 (hu) Humán anti-Il-23 ellenanyagok, készítmények, eljárások és alkalmazások
WO2007007173A3 (fr) Nouveaux anticorps anti-madcam
CR20110470A (es) Proteínas de union a il-17
AU2006279280A8 (en) Methods and compositions for treating neurological disease
EP2197270B8 (fr) Greffons de tissu placentaire et procédés améliorés pour leur préparation et leur utilisation
IL180600A0 (en) Compositions and methods of use for treatment of mammalian diseases
EP1809303A4 (fr) Compositions pharmaceutiques et methodes relatives a l'inhibition d'adherences fibreuses ou de maladies inflammatoires a l'aide de fucanes a basse teneur en sulfate
IL164079A0 (en) Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs
HK1113689A1 (en) Novel cellular compositions and methods for their preparation
IL183435A (en) Lyophilized formulations of keratinocyte growth factor
WO2007118149A3 (fr) Thiazole et thiophene analogues et leur utilisation pour traiter des maladies auto-immunes et des cancers
PL2540319T3 (pl) Przeciwnowotworowe biokoniugaty kwasu hialuronowego lub jego pochodne otrzymane przez pośrednie sprzęganie chemiczne
WO2006017134A3 (fr) Cellules mesendodermiques et cellules de ligne pre-primitive
WO2007014167A3 (fr) Compositions et procedes pour le traitement de maladies epitheliales avec des facteurs de croissance
ZA200800448B (en) Methods and compositions for the prevention and treatment of inflammatory disease
EP1667730A4 (fr) Compositions et procedes pour le traitement de la maladie pulmonaire inflammatoire
WO2005113747A3 (fr) Systemes de culture tissulaire et organique multicellulaires
IL190841A0 (en) Pharmaceutical compositions and diagnostic methods for inflammatory skin diseases, disorders or conditions
ZA200801678B (en) Treatment of inflammatory bowel disease
BRPI0517799A (pt) composição para facilitar o parto humano
ZA200805419B (en) Compositions and methods for preventing or treating inflammatory bowel disease
WO2007022642A3 (fr) Molecules anti-inflammatoires et leurs utilisations
WO2005030927A3 (fr) Procedes et compositions pour le controle de l'inflammation in vivo
EP1805210A4 (fr) Nouveaux peptides et procédés pour le traitement de maladie inflammatoire

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06800289

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06800289

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载